Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Heron Therapeutics (HRTX) EPS (Basic) (2016 - 2025)

Historic EPS (Basic) for Heron Therapeutics (HRTX) over the last 14 years, with Q3 2025 value amounting to -$0.1.

  • Heron Therapeutics' EPS (Basic) fell 23333.33% to -$0.1 in Q3 2025 from the same period last year, while for Sep 2025 it was -$0.08, marking a year-over-year increase of 5000.0%. This contributed to the annual value of -$0.09 for FY2024, which is 8851.26% up from last year.
  • According to the latest figures from Q3 2025, Heron Therapeutics' EPS (Basic) is -$0.1, which was down 23333.33% from -$0.02 recorded in Q2 2025.
  • Heron Therapeutics' 5-year EPS (Basic) high stood at $0.03 for Q4 2024, and its period low was -$0.63 during Q1 2022.
  • In the last 5 years, Heron Therapeutics' EPS (Basic) had a median value of -$0.17 in 2023 and averaged -$0.26.
  • Within the past 5 years, the most significant YoY rise in Heron Therapeutics' EPS (Basic) was 20000.0% (2025), while the steepest drop was 23333.33% (2025).
  • Quarter analysis of 5 years shows Heron Therapeutics' EPS (Basic) stood at -$0.53 in 2021, then skyrocketed by 75.47% to -$0.13 in 2022, then soared by 61.54% to -$0.05 in 2023, then skyrocketed by 154.75% to $0.03 in 2024, then crashed by 465.32% to -$0.1 in 2025.
  • Its last three reported values are -$0.1 in Q3 2025, -$0.02 for Q2 2025, and $0.02 during Q1 2025.